Risedronate for the prevention and treatment of postmenopausal osteoporosis - Wikidata - awgldk - TriplyDB

Risedronate for the prevention and treatment of postmenopausal osteoporosis

Risedronate for the prevention and treatment of postmenopausal osteoporosis

http://www.wikidata.org/entity/Q24245000

about

Bisphosphonates for osteoporosis in people with cystic fibrosis Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation

P2860

Q24197936-9096F4DD-7DE7-485D-94D2-F326BFD63E9D Q35905973-31E272FE-D004-4E05-ACDF-3EBBF89ECFB6

P2860

Risedronate for the prevention and treatment of postmenopausal osteoporosis

http://www.wikidata.org/entity/Q24245000

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@ast

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en-gb

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@nl

type

label

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@ast

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en-gb

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@nl

prefLabel

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@ast

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en-gb

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@nl

P1433

Q24245000-790C3A45-81CE-4EC9-A976-A2B88919210B

P1476

Q24245000-7B0F4F5B-EA57-4CA0-9610-B55F938E2B5A

P2093

Q24245000-0117FFC7-80AB-4AD2-8F28-26C9DEE624DE

Q24245000-0DF7D8C0-4E4B-45A3-8DE5-63792E2E6589

Q24245000-2DD38576-11E0-4AE6-860D-2682457C4F6A

Q24245000-3695ADB0-A7F5-400C-AB3C-45C204F8C83C

Q24245000-6FF4C1D8-3CE6-41A1-9ECB-FFBB768AEE55

Q24245000-848CA2D7-C213-4DC5-89CA-29F318BB9481

Q24245000-8883E9D3-DF96-403C-B3F3-40524AFAE12F

Q24245000-E13908D8-B9E0-4A4E-A58C-BF4586766810

Q24245000-E7D5B7D2-B833-4A77-86BB-4E3220111A6F

Q24245000-FE2355CE-E96C-4748-BF75-8ACBE42D5235

P2860

Q24245000-1E017EC9-4B6D-4AB9-8340-7D62C907FA4F

Q24245000-2799EE2E-6CF1-4AE8-A3B9-C91383125642

Q24245000-4E0D8D40-D43B-40FE-894E-AEB8D36E26C9

Q24245000-59ED63C6-29DE-49FC-A73F-501649CB3F78

Q24245000-6E5DC8FC-6922-4757-A7E2-7FB6E4BD3EC9

Q24245000-936866D1-1CF8-4551-B91B-8961E2D35B2F

Q24245000-C6A000EE-77C7-4788-BCA1-9FCFB65718AE

Q24245000-CBA05581-69A9-4A62-9A23-268BBEC03EE8

Q24245000-D3486FC2-6622-43BA-B8B3-3BC3236980C1

Q24245000-F6A0BB90-AD3E-4E61-A719-D1A74B0E331B

P31

Q24245000-8BBD63A0-EA20-43AB-A8D3-5A3CFE9F0BC6

P356

Q24245000-4B956541-C935-4E90-A05A-33AA2F05636F

P50

Q24245000-121553CA-4B6C-4560-B0FD-FF0334B33CC9

P577

Q24245000-80357553-7D18-43ED-9C79-F617C4DF3FDA

P698

Q24245000-304C953D-A209-4DDC-9D3D-B669691A3A5C

P921

Q24245000-916166F9-A09E-4F20-8A3E-5116D9A9640F

P356

14651858.CD004523.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Risedronate for the prevention and treatment of postmenopausal osteoporosis

@en

P2093

A Cranney

http://www.w3.org/2001/XMLSchema#string

A Papaioannou

http://www.w3.org/2001/XMLSchema#string

B Weaver

http://www.w3.org/2001/XMLSchema#string

BJ Shea

http://www.w3.org/2001/XMLSchema#string

G Guyatt

http://www.w3.org/2001/XMLSchema#string

G Wells

http://www.w3.org/2001/XMLSchema#string

JD Adachi

http://www.w3.org/2001/XMLSchema#string

LM Waldegger

http://www.w3.org/2001/XMLSchema#string

N Zytaruk

http://www.w3.org/2001/XMLSchema#string

VA Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

The statistical basis of meta-analysis.

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.

Bisphosphonate therapy.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

P31

scholarly article

P356

10.1002/14651858.CD004523.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17636764

http://www.w3.org/2001/XMLSchema#string

P921